INTRODUCTION
M u c o s a l h e a l i n g i s currently one of the best available predictors of longterm favorable outcome in patients with inflammatory bowel disease (IBD) [1] [2] [3] [4] [5] . However, colonoscopy is an invasive test and patients are often reluctant to undergo multiple examinations during the course of their disease. Also, the role of endoscopy in patients in remission has never been formally investigated [6] . As a result, noninvasive markers of in ammation have been investigated with the aim of decreasing the need for serial endoscopies. C-reactive protein (CRP) and fecal calprotectin (FC) have been extensively studied in IBD patients [7, 8] for monitoring disease activity and predicting relapse [9] and higher serum CRP and FC levels seem to be accurate predictors of ongoing mucosal in ammation [10, 11] . is is of particular interest since clinical assessment instruments such as Crohn's disease activity index (CDAI) seem to correlate poorly with endoscopic activity [12] . We aimed to determine the ability of noninvasive biomarkers such as FC, CRP and the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) to detect the presence of active intestinal in ammation in IBD patients evaluated endoscopically. 
MATERIAL AND METHODS

Patients
For the purpose of this study we analyzed data from the IBD patients enrolled in the Multimodal Approach in IBD (MAID) cohort currently underway at Colentina Clinical Hospital, Bucharest (NCT01705522): MAID is a prospective observational cohort study investigating clinical, biochemical and endoscopic predictors of relapse in IBD patients. Seventy-seven patients over 18 years of age with a con rmed diagnosis of either Crohn's disease or ulcerative colitis and who had been on stable therapy for at least 4 weeks (excluding corticoid tapering) were enrolled in the MAID cohort between November 2012 and March 2014. Exclusion criteria included refusal to sign the informed consent, concomitant colorectal malignancy or any other severe comorbidities with a life expectancy of less than 12 months. Patients in remission were scheduled for study visits every 6 months while a relapse during this period prompted unscheduled visits for data collection and adjustment of management.
For the current analysis patients who were in clinical remission at the time of their study visit (CDAI score < 150 or Mayo score < 3, respectively) were included. e study design was based on the STARD criteria for diagnostic tests [13] and was approved by the local Ethics Committee.
Disease activity assessment
Clinical activity was assessed using the Mayo score and CDAI for ulcerative colitis and Crohn's disease patients, respectively. Ileo-colonoscopy (Olympus, Exera II 180) was scheduled at baseline and at 12 months, with additional endoscopic examinations at the discretion of the attending physician. Colonoscopy was carried out by endoscopists with experience in IBD who were blinded to the results of noninvasive biomarker tests. e Simple Endoscopic Score for Crohn's Disease (SESCD) and the Mayo endoscopic score were used to grade mucosal in ammation at colonoscopy [14] . Mucosal healing (MH) was pre-de ned as a SESCD score of less than 3 (no ulcerations) for CD patients and a Mayo endoscopic score of 0 for UC patients.
Noninvasive markers of disease activity
Serum and fecal samples were obtained and complete blood count, CRP and FC levels were determined at each visit.
Fecal calprotectin levels were determined using the Buhlmann Quantum Blue Reader®. is is a fast and accessible point-ofcare method for determining calprotectin levels in the range of 30-300 µg/g which has been shown to correlate very well with the ELISA method [15] .
Patients were also asked to complete the SIBDQ [16] at each study visit. e SIBDQ is a simple 10-item questionnaire assessing the quality of life for IBD patients, with values ranging from 1 to 7 and higher scores representing a better quality of life.
Data collection and statistical analysis
Results are expressed as frequencies for categorical variables (further analyzed by Fisher's exact test), mean and standard deviation (SD) for normal continuous variables (Student's t test), and median and extremes for non-normal continuous variables (Mann-Whitney U and Kruskall Wallis tests). Each noninvasive marker (CRP, FC and SIBDQ) was individually evaluated as a diagnostic test for endoscopically active disease; area under the receiver operator characteristic curve (AUROC) was calculated as well as sensitivity and speci city with 95% con dence intervals (95%CI). Binary logistic regression was further applied using FC and SIBDQ as covariates, and a combined test using FC levels and the SIBDQ score was also evaluated. Hypothesis testing was 2-tailed, with p< 0.05 considered statistically signi cant.
e statistical so ware package SPSS for Windows Version 16.0 (SPSS Inc., Chicago, IL) was used to analyze the data.
RESULTS
Forty-eight patients in our study cohort were in clinical remission at the time of colonoscopy and met the inclusion criteria for this current analysis (Fig. 1) . irty-one patients were male (65%) and 29 had ulcerative colitis (60%); mean age of the study population was 37 years (SD 13) ( Table I) .
irty-two patients (67%) had endoscopically active disease at ileo-colonoscopy, de ned as a SESCD score of > 2 or a Mayo endoscopic subscore > 0.
ere was a statistically signi cant di erence between FC levels in patients with endoscopically active disease and those with mucosal healing (219 µg/g versus 123 µg/g, p=0.002, Mann Whitney U). SIBDQ scores were also signi cantly di erent between the two groups, with lower values in the groups with endoscopic disease activity (4.8 vs 5.8, p=0.001). Student t-test). C-reactive protein levels did not show a signi cant di erence between patients with active and inactive disease at colonoscopy (3.4 vs 1.6, p=0.29, Mann Whitney U) (Table II) .
achieved 81% sensitivity and 75% speci city in detecting active endoscopic disease (Table III) . is combined test showed an AUROC of 0.81 (95%CI 0.67-0.95), improving the diagnostic accuracy of either marker alone (Table IV) .
DISCUSSION
Mucosal in ammatory changes and increased biomarker levels have been proven to be strong predictors of diseaserelated outcomes in IBD. However, evidence [17] suggests that most physicians still use a clinical activity score in their everyday practice for patient monitoring, favoring it above endoscopy and biomarkers in the management of their Fecal calprotectin and SIBDQ performed well in discriminating between patients with active and inactive disease at colonoscopy. At the cut-o value of 30µg/g, FC showed a 93% sensitivity and 50% speci city for detecting active mucosal disease, with an AUROC of 0.77 (95%CI 0.62 -0.91). SIBDQ values above 6 had a 86% sensitivity and a 53% speci city for mucosal healing and an AUROC of 0.78 (95%CI 0.65 -0.91) (Figs. 2, 3 ). C-reactive protein was not useful as a diagnostic test for mucosal in ammation, with an AUROC of 0.59 (95%CI 0.41-0.72).
In order to increase the speci city of noninvasive biomarker assessment of mucosal in ammatory changes, we explored a combination of FC levels and the SIBDQ score. In a biomarker panel test, using FC levels > 30µg/g and a SIBDQ score < 6 we patients. e invasive and cumbersome nature of colonoscopy might contribute to the low acceptance levels among both clinicians and patients. In our study, we evaluated the accuracy of selected noninvasive biomarkers in detecting the presence of endoscopically active disease in IBD patients who were in clinical remission.
e results from our study con rm previously published data showing a good correlation between active mucosal in ammation and FC levels. In our cohort, FC was a better predictor of mucosal in ammation than CRP levels, consistent with data from other studies [18, 19] . e SIBDQ score was signi cantly lower in patients showing endoscopic evidence of mucosal in ammation than in patients with inactive disease. To the best of our knowledge, this is the rst study investigating the correlation between endoscopic activity and the SIBDQ.
ese results take us a step further in con rming the value of noninvasive biomarkers in evaluating IBD patients in clinical remission. Mucosal healing is an important predictor of disease-related outcomes, with emerging data proving increased relapse rates for patients in clinical remission who have active mucosal in ammation at endoscopy [5] . However, current guidelines [14] do not recommend repeating endoscopy for patients in clinical remission unless this could alter the therapeutic management. Consequently, noninvasive biomarkers that can accurately discriminate between endoscopically active and inactive disease become increasingly important to daily practice.
DeVos et al [9] have shown that ulcerative colitis patients in remission have mean FC levels < 30µg/g and that an increase in baseline levels is associated with clinical ares and relapse. Using the same cut-o value, we calculated a 93% sensitivity for FC in detecting mucosal activity in IBD patients in clinical remission.
In our study, both FC and the SIBDQ showed high sensitivity but relatively low specificity in detecting active mucosal in ammation. ese ndings are in accordance with current data showing that, while FC is useful in detecting active endoscopic disease in both CD and ulcerative colitis, the overall accuracy of this test is limited [20] . Furthermore, this observation is also true in regard to the use of FC levels as predictors of disease relapse in IBD patients currently in remission [21, 22] . We addressed this issue by conducting an analysis using a combination of FC levels > 30µg/g and a SIBDQ score < 6 to improve the diagnostic accuracy of FC alone. While other studies have also explored the possibility of combining biomarkers such as CRP and FC with the aim of increasing the overall diagnostic accuracy [23] , our study is the rst one to use a patient-oriented tool (SIBDQ). We modeled our approach on the 
Fig. 4. Receiver Operator Characteristic Curve (ROC)
showing the diagnostic performance of a combined test using fecal calprotectin levels > 30 µg/g and a SIBDQ score < 6 in detecting active mucosal in ammation.
fact that validated disease activity scores such as the CDAI also employ patient-reported outcomes such as abdominal pain and wellbeing. In our cohort, we calculated that a subject ful lling both of the above criteria has a 88% probability (95% CI 76-95%) of showing active endoscopic disease, while a patient with FC levels of < 30µg/g and a SIBDQ score > 6 has a 94% probability (95%CI 84-98.4%) of mucosal healing at endoscopy (Table IV) . e most important aspect of these ndings is the possibility of correctly identifying patients with mucosal healing and sparing them from unnecessary endoscopic examinations. Such patients in deep remission could, in the future, be monitored with the use of noninvasive biomarkers.
Several limitations in our study underline the need for further research and external validation of our data. is is a single-center study including a relatively small number of patients with both Crohn's disease and ulcerative colitis. Also, the cut-o values for FC need to be further explored, with proposed values varying between 30 and 250 µg/g in di erent studies [20, 24, 25] . In our algorithm we chose to use the 30 µg/g cut-o value for FC levels. We favored this value because it yielded the highest sensitivity for detecting mucosal in ammation. Choosing a cut-o value for a given parameter usually implies a trade-o between sensitivity and speci city. D'Haens et al used a higher cut-o value of 250 µg/g in their study, resulting in higher speci city but lower sensitivity in detecting mucosal in ammation [20] . In this particular setting, we consider it more prudent to aim for increased sensitivity allowing us to detect potential candidates for endoscopic evaluation. Since speci city was low (50%) at our selected cuto value of 30 µg/g we subsequently combined FC levels and the SIBDQ score resulting in an improvement of overall diagnostic accuracy (AUROC 0.814, speci city 81.2%, sensitivity 75%).
Another potential limitation might be that, while there are no available data suggesting that FC levels should be interpreted di erently in Crohn's disease versus ulcerative colitis, it is conceivable that separate validation for each patient subgroup might be warranted. Accordingly, data from multicenter trials on larger number of patients are required to validate our proposed diagnostic algorithm.
CONCLUSION
Our analysis presents robust data that justify further research in this eld, with an emphasis on exploring panels of selected noninvasive biomarkers in the assessment of IBD patients.
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